Invention Grant
US08969583B2 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
有权
3-苯基-5-脲基异噻唑-4-甲酰胺和3-氨基-5-苯基异噻唑衍生物作为激酶抑制剂
- Patent Title: 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
- Patent Title (中): 3-苯基-5-脲基异噻唑-4-甲酰胺和3-氨基-5-苯基异噻唑衍生物作为激酶抑制剂
-
Application No.: US13728502Application Date: 2012-12-27
-
Publication No.: US08969583B2Publication Date: 2015-03-03
- Inventor: Thomas C. Malone , C. Eugene Hull , Sougato Boral , Julie A. Wurster , Michael R. Robinson , Jeffrey L. Edelman
- Applicant: Allergan, Inc.
- Applicant Address: US CA Irvine
- Assignee: Allergan, Inc.
- Current Assignee: Allergan, Inc.
- Current Assignee Address: US CA Irvine
- Agent Mark D. Kafka
- Main IPC: C07D275/03
- IPC: C07D275/03 ; C07D417/12 ; A61K31/5377 ; A61K31/425 ; A61K31/427 ; C07D295/13
Abstract:
This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
Public/Granted literature
Information query
